SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001047469-18-004571
Filing Date
2018-06-19
Accepted
2018-06-19 16:17:26
Documents
5
Period of Report
2018-08-01
Effectiveness Date
2018-06-19

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2235997zdef14a.htm DEF 14A 625077
2 G285256.JPG g285256.jpg GRAPHIC 21176
3 G761950.JPG g761950.jpg GRAPHIC 7584
4 G151972BGI001.GIF g151972bgi001.gif GRAPHIC 178491
5 G151972BGI002.GIF g151972bgi002.gif GRAPHIC 117464
  Complete submission text file 0001047469-18-004571.txt   1073884
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37558 | Film No.: 18907332
SIC: 2834 Pharmaceutical Preparations